TABLE 2.
Comparison of clinicopathologic characteristics between AA responders and non‐responders
| Variables | AA responders (N = 57) | AA non‐responders (N = 75) | p Value |
|---|---|---|---|
| Age (years) | 71.00 (51.00–85.00) | 71.50 (36.00–84.00) | 0.716 |
| BMI (kg/m2) | 23.72 (13.51–30.86) | 24.16 (18.72–29.74) | 0.385 |
| ECOG score | |||
| 0 or 1 | 38 (66.67%) | 48 (64%) | 0.750 |
| 2 | 19 (33.33%) | 27 (36%) | |
| ISUP grading group | |||
| 1 | 7 (12.28%) | 5 (6.67%) | 0.206 |
| 2 | 12 (21.05%) | 10 (13.33%) | |
| 3 | 17 (29.82%) | 17 (22.67%) | |
| 4 | 14 (24.57%) | 31 (41.33%) | |
| 5 | 7 (12.28%) | 12 (16%) | |
| Clinical T stage | |||
| 2 | 7 (12.28%) | 14 (18.67%) | 0.284 |
| 3 | 28 (49.12%) | 27 (36%) | |
| 4 | 22 (38.60%) | 34 (45.33%) | |
| ADT duration before AA | |||
| <12 months | 16 (28.07%) | 51 (68%) | <0.001 |
| ≥12 months | 41 (71.93%) | 24 (32%) | |
| Metastatic sites | |||
| Bone only | 39 (68.42%) | 25 (33.33%) | <0.001 |
| Viscera | 18 (31.58%) | 50 (66.67%) | |
| PSA at diagnosis (ng/ml) | 12.93 (4.78–42.40) | 13.00 (4.10–96.00) | 0.448 |
| PSA at abiraterone start (ng/ml) | 9.53 (1.11–91.76) | 9.33 (1.64–77.07) | 0.889 |
| PSA nadir after AA treatment (ng/ml) | 1.27 (0.02–10.81) | 8.865 (1.04–48.12) | <0.001 |
| PSA reduction (%) | 84.77 (55.08–99.51) | 20.80 (−87.10–46.94) | <0.001 |
| SMI (cm2/m2) | 51.84 (40.18–76.55) | 45.96 (32.15–61.17) | <0.001 |
| VFA (cm2) | 112.65 (55.85–216.53) | 134.53 (79.67–194.64) | 0.005 |
| SFA (cm2) | 134.52 (82.35–185.43) | 134.56 (76.55–201.32) | 0.772 |
| TFA (cm2) | 250.85 (150.21–384.09) | 271.33 (165.50–385.54) | 0.107 |
| rVFA | 0.46 (0.33–0.57) | 0.49 (0.38–0.57) | 0.001 |
| PPFA (cm2) | 11.16 (5.52–18.29) | 14.56 (7.95–21.47) | <0.001 |
| PPFA/PA | 0.80 (0.42–1.56) | 1.39 (0.66–2.50) | <0.001 |
| PPFT (mm) | 8.32 (1.25–16.32) | 9.58 (1.23–16.59) | 0.013 |
| PPFT/SFT | 0.30 (0.08–0.53) | 0.34 (0.05–0.72) | 0.01 |
| Biochemical progression | |||
| Yes | 31 (54.39%) | 67 (89.33%) | <0.001 |
| No | 26 (45.61%) | 8 (10.67%) | |
| Radiological progression | |||
| Yes | 25 (43.86%) | 62 (82.67%) | <0.001 |
| No | 32 (56.14%) | 13 (17.33%) |
Abbreviations: AA, abiraterone acetate; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group performance status score; ISUP, International Society of Urological Pathology; PPFA/PA, periprostatic fat area/prostate area; PPFA, periprostatic fat area; PPFT/SFT, periprostatic fat thickness/subcutaneous fat thickness; PPFT, periprostatic fat thickness; PSA, prostate‐specific antigen; rVFA, relative visceral fat area; SFA, subcutaneous fat area; SMI, skeletal muscle index; TFA, total fat area; VFA, visceral fat area.